Employer Coverage of GLP-1 Drugs Drops Sharply, Threatening Lilly's Zepbound
LLY sits 80% above its 52-week low of $694.23 on light trading volume (0.1× avg).
Summary
A Business Group on Health survey shows 14% of US employers plan to drop GLP-1 weight-loss drug coverage in 2027, with overall employer coverage falling from 72% in 2025 to 60% in 2026. This directly threatens demand for Lilly's Zepbound and Foundayo, which are key growth drivers. Rising healthcare costs, projected to increase 9.2% in 2027, are pushing employers to cut specialty drug coverage. The trend could pressure Lilly's obesity franchise revenue, especially as competitors like Novo Nordisk face similar headwinds. Watch for Lilly's response and any updates to its 2027 guidance.
At the time of this announcement, LLY was trading at $1,252.86 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $694.23 to $1,292.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.